Swedish DPI company Iconovo said that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance regarding a patent covering Iconovo’s ICOres reservoir-based dry powder inhaler. The patent, titled “Dry Powder Inhaler,” describes the design of the ICOres device. The company was granted a Japanese patent for ICOres in November 2019 and has also been granted patents in Sweden, Europe, and China.
Amneal is currently developing a generic version of Symbicort that is based on the ICOres inhaler. In July 2019, Iconovo announced that a PK study showed that ICOres delivered budesonide/formoterol as expected when compared to Symbicort Turbuhaler.
Iconovo CEO Johan Wäborg commented, “USA is the biggest market in the world. With a granted patent in USA we can now intensify our global business development. This patent means that ICOres has broad international patent protection, which increases the value of our product portfolio.”
Read the Iconovo announcement.
